

Robert L Ferris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/768180/publications.pdf>

Version: 2024-02-01

434
papers

33,929
citations

3919

88
h-index

5364

164
g-index

445
all docs

445
docs citations

445
times ranked

33366
citing authors

#	ARTICLE	IF	CITATIONS
1	The Nasoseptal Flap for Reconstruction of Lateral Oropharyngectomy Defects: A Clinical Series. <i>Laryngoscope</i> , 2022, 132, 53-60.	1.1	4
2	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). <i>Journal of Clinical Oncology</i> , 2022, 40, 138-149.	0.8	162
3	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	1.9	18
4	Poor treatment tolerance in head and neck cancer patients with low muscle mass. <i>Head and Neck</i> , 2022, 44, 844-850.	0.9	6
5	Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1335-1344.	3.2	14
6	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. <i>Frontiers in Oncology</i> , 2022, 12, 730785.	1.3	1
7	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). <i>Clinical Infectious Diseases</i> , 2022, 75, e630-e644.	2.9	65
8	Reply to A.S. Garden. <i>Journal of Clinical Oncology</i> , 2022, 40, 1133-1134.	0.8	0
9	Unmet Needs and Perspectives in Oral Cancer Prevention. <i>Cancers</i> , 2022, 14, 1815.	1.7	14
10	Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adults. <i>Tumour Virus Research</i> , 2022, 13, 200237.	1.5	5
11	The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1333-1337.	3.0	5
12	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. <i>Cancer Immunology Research</i> , 2022, 10, 885-899.	1.6	7
13	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. <i>Cancers</i> , 2022, 14, 2639.	1.7	4
14	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€“2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
15	EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	9
16	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. <i>International Journal of Radiation Biology</i> , 2021, 97, 1121-1128.	1.0	30
17	TORS Baseâ€“ofâ€“Tongue Mucosectomy in Human Papilloma Virusâ€“Negative Carcinoma of Unknown Primary. <i>Laryngoscope</i> , 2021, 131, 78-81.	1.1	15
18	<sc>PET</sc>/<sc>CT</sc> Poorly Predicts <sc>AJCC</sc> 8th Edition Pathologic Staging in <sc>HPV</sc>â€“Related Oropharyngeal Cancer. <i>Laryngoscope</i> , 2021, 131, 1535-1541.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model. <i>Oncolimmunology</i> , 2021, 10, 1912473.	2.1	8
20	Elective neck dissection versus positron emission tomographyâ€“computed tomographyâ€“guided management of the neck in clinically nodeâ€“negative early oral cavity cancer: A costâ€“utility analysis. <i>Cancer</i> , 2021, 127, 1993-2002.	2.0	2
21	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched caseâ€“control study. <i>Cancer</i> , 2021, 127, 1779-1787.	2.0	38
22	Characterizing p<scp>ostoperative</scp> physiologic swallow function following transoral robotic surgery for early stage tonsil, base of tongue, and unknown primary human papillomavirus<scp>â€“associated</scp> squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 1629-1640.	0.9	7
23	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. <i>Science Advances</i> , 2021, 7, .	4.7	28
24	Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 651123.	1.3	0
25	Perceived Financial Insecurity Impacts Healthcare Decisionâ€“Making Among Patients With Sinusitis. <i>Laryngoscope</i> , 2021, 131, 2403-2412.	1.1	3
26	CD40 Agonist Targeted to Fibroblast Activation Protein Î± Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4054-4065.	3.2	18
27	Reply to N. Hirshoren et al and D. Chakrabarti et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 1600-1601.	0.8	1
28	Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. , 2021, 9, e002088.		59
29	Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: Results from an EORTC led survey. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1261-1265.	0.5	4
30	Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6010-6010.	0.8	20
31	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2844-2858.	0.9	12
32	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2882.	1.7	6
33	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. , 2021, 9, e002568.		87
34	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 3349.	5.8	142
35	The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors. <i>Head and Neck</i> , 2021, 43, 3062-3075.	0.9	17
36	Epidermal Growth Factor Receptor-Targeted Therapy for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 743-749.	0.5	7

#	ARTICLE	IF	CITATIONS
37	APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Viruses</i> , 2021, 13, 1666.	1.5	16
38	Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2732-2733.	0.8	7
39	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. <i>JID Innovations</i> , 2021, 1, 100045.	1.2	5
40	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. <i>Cell Reports</i> , 2021, 36, 109699.	2.9	37
41	HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures. <i>Carcinogenesis</i> , 2021, 42, 14-20.	1.3	8
42	Surgical factors associated with patient-reported quality of life outcomes after free flap reconstruction of the oral cavity. <i>Oral Oncology</i> , 2021, 123, 105574.	0.8	4
43	Quality of life and health-related utility after trans-oral surgery for head and neck cancers. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 250.	1.0	2
44	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. <i>Nature Communications</i> , 2021, 12, 6340.	5.8	17
45	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. <i>Nature Communications</i> , 2021, 12, 7338.	5.8	104
46	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. <i>Science Translational Medicine</i> , 2021, 13, eabf8495.	5.8	16
47	Reconstruction of TORS oropharyngectomy defects with the nasoseptal flap via transpalatal tunnel. <i>Journal of Robotic Surgery</i> , 2020, 14, 311-316.	1.0	8
48	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. <i>Cancer</i> , 2020, 126, 37-45.	2.0	11
49	The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma. <i>Journal of Pathology</i> , 2020, 250, 107-119.	2.1	11
50	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. <i>Immunity</i> , 2020, 52, 183-199.e9.	6.6	383
51	Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers. <i>Oral Oncology</i> , 2020, 100, 104475.	0.8	16
52	Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3983-3986.	0.8	15
53	A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. <i>Oral Oncology</i> , 2020, 110, 104797.	0.8	32
54	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020, 5, .	5.6	36

#	ARTICLE	IF	CITATIONS
55	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 3141-3152.	0.9	28
56	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
57	Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development. <i>Cancers</i> , 2020, 12, 3577.	1.7	4
58	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. <i>Scientific Reports</i> , 2020, 10, 8031.	1.6	12
59	Proposal of a timing strategy for cholesteatoma surgery during the COVID-19 pandemic. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2619-2623.	0.8	10
60	Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity. <i>Frontiers in Oncology</i> , 2020, 10, 688.	1.3	20
61	A new endoscopic surgical approach to the larynx, hypopharynx, and neck lymphatics: The roboticâ€assisted extended â€Sistrunkâ€approach (RESA). <i>Head and Neck</i> , 2020, 42, 2750-2756.	0.9	3
62	Phase I Study of Ficlatusumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 1537.	1.7	19
63	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	1.1	36
64	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	0.8	40
65	Promising progress from Healthy People 2020 and cancer incidence update. <i>Cancer</i> , 2020, 126, 2114-2115.	2.0	0
66	Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 83.	1.3	5
67	Twoâ€year followâ€up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (<sc>CheckMate</sc> 141). <i>Head and Neck</i> , 2020, 42, 2852-2862.	0.9	26
68	Best Practice in Surgical Treatment of Malignant Head and Neck Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 140.	1.3	12
69	Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. <i>Oral Oncology</i> , 2020, 107, 104734.	0.8	44
70	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. <i>Annals of Oncology</i> , 2020, 31, 942-950.	0.6	240
71	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
72	Potential impact of the <sc>COVID</sc>â€19 pandemic on financial toxicity in cancer survivors. <i>Head and Neck</i> , 2020, 42, 1332-1338.	0.9	60

#	ARTICLE	IF	CITATIONS
73	Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience. <i>Head and Neck</i> , 2020, 42, 1310-1316.	0.9	64
74	Major head and neck reconstruction during the COVID-19 pandemic: The University of Pittsburgh approach. <i>Head and Neck</i> , 2020, 42, 1243-1247.	0.9	16
75	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2476-2487.	0.8	152
76	HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. <i>Journal of Clinical Investigation</i> , 2020, 130, 1635-1652.	3.9	104
77	Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6500-6500.	0.8	79
78	Improving responses to immunotherapy in head and neck squamous cell carcinoma. , 2020, , 107-133.		0
79	Immunotherapeutic approaches in HNSCC. , 2020, , 117-142.		1
80	Dose-response model for severe late laryngeal toxicity after stereotactic body radiation therapy for previously-irradiated head and neck cancer. <i>Journal of Radiosurgery and SBRT</i> , 2020, 7, 89-94.	0.2	2
81	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 96, 140-147.	0.8	46
82	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
83	Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response. <i>Cancers</i> , 2019, 11, 951.	1.7	8
84	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. <i>Oral Oncology</i> , 2019, 95, 106-114.	0.8	18
85	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019, 96, 7-14.	0.8	45
86	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	3.2	115
87	Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 464.	1.3	61
88	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	2.0	64
89	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study—Part 1 (Head and Neck Surgery). <i>Frontiers in Oncology</i> , 2019, 9, 1125.	1.3	4
90	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study—Part 2 (Radiation Oncology). <i>Frontiers in Oncology</i> , 2019, 9, 1126.	1.3	3

#	ARTICLE	IF	CITATIONS
91	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Studyâ€”Part 3 (Medical Oncology). <i>Frontiers in Oncology</i> , 2019, 9, 1127.	1.3	1
92	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Studyâ€”Part 4 (Biomarkers). <i>Frontiers in Oncology</i> , 2019, 9, 1128.	1.3	3
93	PD-1 immunotherapy for recurrent or metastatic HNSCC. <i>Lancet, The</i> , 2019, 394, 1882-1884.	6.3	16
94	Immunotherapy for head and neck cancer: Recent advances and future directions. <i>Oral Oncology</i> , 2019, 99, 104460.	0.8	202
95	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. <i>Immunity</i> , 2019, 51, 548-560.e4.	6.6	88
96	Sparing Cardiac Substructures With Optimized Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e473-e481.	1.1	24
97	A systematic review and meta-analysis of margins in transoral surgery for oropharyngeal carcinoma. <i>Oral Oncology</i> , 2019, 98, 69-77.	0.8	48
98	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
99	Response to Letter to the Editor regarding follow-up for NIFTP. <i>Head and Neck</i> , 2019, 41, 835-835.	0.9	1
100	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 419-427.	4.2	46
101	Otogenic Pneumocephalus Presenting as Pneumatocele of the Scalp. <i>American Journal of Medicine</i> , 2019, 132, 1170-1172.	0.6	1
102	Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage. <i>Cancer</i> , 2019, 125, 3198-3207.	2.0	24
103	Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1683-1685.	0.8	7
104	The changing therapeutic landscape of head and neck cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 669-683.	12.5	454
105	Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base. <i>Cancer</i> , 2019, 125, 2782-2793.	2.0	40
106	Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. <i>Head and Neck</i> , 2019, 41, 3056-3063.	0.9	14
107	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. <i>Oncolmmunology</i> , 2019, 8, e1593805.	2.1	110
108	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2591-2601.	0.9	12

#	ARTICLE	IF	CITATIONS
109	Transoral tongue base mucosectomy for the identification of the primary site in the work-up of cancers of unknown origin: Systematic review and meta-analysis. <i>Oral Oncology</i> , 2019, 91, 97-106.	0.8	49
110	Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III. <i>Head and Neck</i> , 2019, 41, 1178-1183.	0.9	6
111	Hypopharyngeal cancer treatment: Does initial surgery confer survival benefit?. <i>Head and Neck</i> , 2019, 41, 2167-2173.	0.9	12
112	Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers. <i>Radiotherapy and Oncology</i> , 2019, 131, 192-201.	0.3	19
113	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
114	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. <i>Head and Neck</i> , 2019, 41, 843-856.	0.9	10
115	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. <i>JAMA Oncology</i> , 2019, 5, 204.	3.4	317
116	Hemorrhagic and Cystic Brain Metastases Are Associated With an Increased Risk of Leptomeningeal Dissemination After Surgical Resection and Adjuvant Stereotactic Radiosurgery. <i>Neurosurgery</i> , 2019, 85, 632-641.	0.6	25
117	Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. <i>Laryngoscope</i> , 2019, 129, 162-169.	1.1	62
118	Dose-response modeling the risk of carotid bleeding events after stereotactic body radiation therapy for previously irradiated head and neck cancer. <i>Journal of Radiosurgery and SBRT</i> , 2019, 6, 83-89.	0.2	2
119	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. <i>Oncolmmunology</i> , 2018, 7, e1442168.	2.1	64
120	STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. <i>Oral Oncology</i> , 2018, 78, 186-193.	0.8	42
121	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 22.	1.8	131
122	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	0.8	589
123	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. <i>Cancer</i> , 2018, 124, 1682-1690.	2.0	274
124	Thyroidectomy in patients who have undergone gastric bypass surgery. <i>Head and Neck</i> , 2018, 40, 1237-1244.	0.9	15
125	Perineural Invasion in Parotid Gland Malignancies. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 1035-1041.	1.1	50
126	Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 195-200.	0.4	29

#	ARTICLE	IF	CITATIONS
127	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018, 77, 92-97.	0.8	7
128	Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer. <i>International Journal of Cancer</i> , 2018, 142, 2518-2528.	2.3	25
129	Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4529-4538.	3.2	82
130	Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma. <i>Journal of Radiation Oncology</i> , 2018, 7, 187-193.	0.7	5
131	Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1743-1751.	0.9	7
132	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 595-605.	0.4	101
133	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018, 124, 84-94.	2.0	22
134	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. <i>Clinical Cancer Research</i> , 2018, 24, 62-72.	3.2	64
135	Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 100-106.	0.3	21
136	Role of Immunotherapy in Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 12-16.	1.0	62
137	Staged Reconstruction (Delayed-Immediate) of the Maxillectomy Defect Using CAD/CAM Technology. <i>Journal of Reconstructive Microsurgery</i> , 2018, 34, 193-199.	1.0	13
138	Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 660-666.	1.1	20
139	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
140	Reproducibility in contouring the neurovascular bundle for prostate cancer radiation therapy. <i>Practical Radiation Oncology</i> , 2018, 8, e125-e131.	1.1	10
141	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. <i>Journal of Clinical Investigation</i> , 2018, 128, 3926-3940.	3.9	136
142	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC)., 2018, , 341-355.		2
143	Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018, 25, 2208-2222.e7.	2.9	30
144	Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment. <i>Oral Oncology</i> , 2018, 87, 170-176.	0.8	29

#	ARTICLE	IF	CITATIONS
145	T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. <i>Oncolimmunology</i> , 2018, 7, e1494112.	2.1	29
146	PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2018, 6, 1548-1560.	1.6	122
147	Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. <i>Current Treatment Options in Oncology</i> , 2018, 19, 68.	1.3	14
148	The addition of chemotherapy in the definitive management of high risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 475-487.	0.8	6
149	Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. <i>Cell Reports</i> , 2018, 25, 1332-1345.e5.	2.9	66
150	Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group Position paper based on the EORTC 1420 "Best of"™ and 24954 "larynx preservation"™ study. <i>European Journal of Cancer</i> , 2018, 103, 69-77.		15
151	EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. <i>PLoS ONE</i> , 2018, 13, e0203402.	1.1	22
152	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. <i>Head and Neck</i> , 2018, 40, 1685-1690.	0.9	25
153	Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. <i>Clinical Cancer Research</i> , 2018, 24, 4242-4255.	3.2	114
154	AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. <i>Head and Neck</i> , 2018, 40, 1881-1888.	0.9	41
155	Transoral robotic-assisted supracricoid partial laryngectomy with cricohyoidoepiglottopexy: Procedure development and outcomes of initial cases. <i>Head and Neck</i> , 2018, 40, 2254-2262.	0.9	10
156	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2018, 4, 1583.	3.4	84
157	Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer. <i>Scientific Reports</i> , 2018, 8, 10716.	1.6	9
158	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018, 124, 3586-3595.	2.0	5
159	Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort. <i>Oral Oncology</i> , 2018, 84, 82-87.	0.8	22
160	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	1.9	70
161	P16 as a Prognostic Biomarker for Nonoropharyngeal Squamous Cell Cancers: Avatar or Mirage?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1290-1291.	3.0	6
162	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Cancer Research</i> , 2018, , 365-396.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Use of Intraoperative Indocyanine Green Endoscopy in the Assessment of Vascularity of Intranasal Flaps. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.4	0
164	Endonasal Suturing of Nasoseptal Flap to the Nasopharyngeal Fascia Using the V-Loc Wound Closing Device. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.4	0
165	Perineural Spread of Squamous Cell Carcinoma to the Skull Base following Treatment of Oropharyngeal P16-Positive Squamous Cell Carcinoma: A Case Series. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.4	0
166	Association of Lymphovascular Space Invasion With Locoregional Failure and Survival in Patients With Node-Negative Oral Tongue Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 382.	1.2	35
167	Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically. <i>Oral Oncology</i> , 2017, 65, 89-93.	0.8	23
168	Minimizing adjuvant treatment after transoral robotic surgery through surgical margin revision and exclusion of radiographic extracapsular extension: A Prospective observational cohort study. <i>Head and Neck</i> , 2017, 39, 965-973.	0.9	23
169	Oncogenic growth factor signaling mediating tumor escape from cellular immunity. <i>Current Opinion in Immunology</i> , 2017, 45, 52-59.	2.4	19
170	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynxâ€”ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 490-497.	0.8	359
171	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. <i>Head and Neck</i> , 2017, 39, 840-852.	0.9	34
172	Transoral robotic surgery for management of cervical unknown primary squamous cell carcinoma: Updates on efficacy, surgical technique and margin status. <i>Oral Oncology</i> , 2017, 66, 9-13.	0.8	52
173	Rising incidence of oral tongue cancer among white men and women in the United States, 1973â€”2012. <i>Oral Oncology</i> , 2017, 67, 146-152.	0.8	124
174	Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 542.	1.2	28
175	THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2307-2312.	3.3	58
176	Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 408-416.	1.6	84
177	Solid Lymph Nodes as an Imaging Biomarker for Risk Stratification in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Neuroradiology</i> , 2017, 38, 1405-1410.	1.2	18
178	A prospective evaluation of short-term dysphagia after transoral robotic surgery for squamous cell carcinoma of the oropharynx. <i>Cancer</i> , 2017, 123, 3132-3140.	2.0	32
179	Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 806-812.	0.4	22
180	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	1.9	23

#	ARTICLE	IF	CITATIONS
181	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. <i>Oncolmmunology</i> , 2017, 6, e1329071.	2.1	85
182	Interferon- β Drives Treg Fragility to Promote Anti-tumor Immunity. <i>Cell</i> , 2017, 169, 1130-1141.e11.	13.5	431
183	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 76, 152-166.	1.3	82
184	The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 483.	3.4	51
185	Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. <i>Oncolmmunology</i> , 2017, 6, e1261779.	2.1	235
186	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. <i>Molecular Cancer Research</i> , 2017, 15, 179-188.	1.5	19
187	Defining the Prevalence and Prognostic Value of Perineural Invasion and Angiolymphatic Invasion in Human Papillomavirus-Positive Oropharyngeal Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1236.	1.2	18
188	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 2433-2443.	0.9	5
189	Human papillomavirus 16 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. <i>Cancer</i> , 2017, 123, 4382-4390.	2.0	67
190	PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. <i>Cancer Research</i> , 2017, 77, 6353-6364.	0.4	161
191	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017, 73, 138-146.	0.8	90
192	National evaluation of multidisciplinary quality metrics for head and neck cancer. <i>Cancer</i> , 2017, 123, 4372-4381.	2.0	59
193	Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. <i>Oral Oncology</i> , 2017, 75, 184-188.	0.8	21
194	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1104-1115.	5.1	325
195	Postoperative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities. <i>Practical Radiation Oncology</i> , 2017, 7, e419-e425.	1.1	11
196	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 707-716.	3.2	104
197	Optimal Perioperative Care in Major Head and Neck Cancer Surgery With Free Flap Reconstruction. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 292.	1.2	351
198	Management of Pharyngeal Fistulas After Anterior Cervical Spine Surgery. <i>Clinical Spine Surgery</i> , 2017, 30, E25-E30.	0.7	5

#	ARTICLE	IF	CITATIONS
199	Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. <i>Frontiers in Pharmacology</i> , 2017, 8, 382.	1.6	36
200	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	1.8	193
201	Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 332.	1.6	25
202	Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery. <i>Head and Neck</i> , 2017, 39, 1510-1515.	0.9	46
203	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017, 2, e90449.	2.3	45
204	Evaluation of Intranasal Flap Perfusion by Intraoperative ICG Fluorescence Angiography. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.4	0
205	Utility of upâ€front transoral robotic surgery in tailoring adjuvant therapy. <i>Head and Neck</i> , 2016, 38, 1201-1207.	0.9	31
206	Externalâ€beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016, 38, 493-498.	0.9	76
207	Oncologic outcomes of surgically treated earlyâ€stage oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1467-1471.	0.9	24
208	Transthyrohyoid access to the larynx for endoscopic resection of earlyâ€stage glottic cancer. <i>Head and Neck</i> , 2016, 38, 1286-1289.	0.9	3
209	Current Role of Surgery in the Management of Oropharyngeal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1176-1183.	2.5	21
210	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5229-5237.	3.2	107
211	Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. <i>Oral Oncology</i> , 2016, 53, 60-66.	0.8	8
212	Characterization of human papillomavirus antibodies in individuals with head and neck cancer. <i>Cancer Epidemiology</i> , 2016, 42, 46-52.	0.8	32
213	Is There a Role for Robotic Surgery in the Treatment of Head and Neck Cancer?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 29.	1.3	24
214	Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw033.	3.0	19
215	Immunology of Head and Neck Cancer. , 2016, , 133-148.		0
216	Tumor-infiltrating Tim-3 ⁺ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. <i>Oncolmmunology</i> , 2016, 5, e1200778.	2.1	47

#	ARTICLE	IF	CITATIONS
217	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. <i>Cancers of the Head & Neck</i> , 2016, 1, 12.	6.2	17
218	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	13.9	3,845
219	The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. <i>Immunity</i> , 2016, 45, 374-388.	6.6	504
220	Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, <i>PLAG1</i> or <i>HMGA2</i> rearrangements, and common genetic alterations. <i>Cancer</i> , 2016, 122, 3136-3144.	2.0	73
221	Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 60, 55-60.	0.8	21
222	Risk factors for radiation failure in early-stage glottic carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2016, 62, 90-100.	0.8	42
223	Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2016, 62, 60-71.	0.8	156
224	Factors Influencing the Incidence of Severe Complications in Head and Neck Free Flap Reconstructions. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2016, 4, e1013.	0.3	15
225	Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1613-7.	0.9	17
226	Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 973-980.	0.4	55
227	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. <i>Oral Oncology</i> , 2016, 58, 52-58.	0.8	58
228	Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. <i>Cancer</i> , 2016, 122, 2021-2030.	2.0	30
229	Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E494-501.	0.9	17
230	Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx. <i>Head and Neck</i> , 2016, 38, E2143-50.	0.9	45
231	Utility of a perioperative nutritional intervention on postoperative outcomes in high-risk head & neck cancer patients. <i>Oral Oncology</i> , 2016, 54, 42-46.	0.8	32
232	Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2016, 37, 522-529.	1.3	75
233	Utility of Diagnostic Molecular Markers for Evaluation of Indeterminate Thyroid Nodules. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 421.	1.2	10
234	Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. <i>Journal of Immunology</i> , 2016, 196, 2870-2878.	0.4	19

#	ARTICLE	IF	CITATIONS
235	Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice. <i>Cancer Immunology Research</i> , 2016, 4, 441-451.	1.6	31
236	A 20-Year Review of 75 Cases of Salivary Duct Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 489.	1.2	114
237	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN γ That Induce PD-L1 Expression in Head and Neck Cancer. <i>Cancer Research</i> , 2016, 76, 1031-1043.	0.4	265
238	Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. <i>American Journal of Medicine</i> , 2016, 129, e29-e31.	0.6	2
239	HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. <i>Annual Review of Medicine</i> , 2016, 67, 91-101.	5.0	97
240	Analysis of post-transoral robotic-assisted surgery hemorrhage: Frequency, outcomes, and prevention. <i>Head and Neck</i> , 2016, 38, E776-82.	0.9	82
241	Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6009-6009.	0.8	32
242	MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. <i>BMC Cancer</i> , 2015, 15, 861.	1.1	34
243	Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. , 2015, 3, 54.		40
244	Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners. <i>Head and Neck</i> , 2015, 37, 1282-1289.	0.9	53
245	Accuracy of computed tomography to predict extracapsular spread in p16-positive squamous cell carcinoma. <i>Laryngoscope</i> , 2015, 125, 1613-1618.	1.1	48
246	Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. <i>Annals of Surgery</i> , 2015, 262, 519-525.	2.1	100
247	Response to Letter to the Editor on COI for American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules. <i>Thyroid</i> , 2015, 25, 1266-1266.	2.4	1
248	Transoral Robotic Surgery Alone for Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 499.	1.2	68
249	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. <i>Cancer Immunology Research</i> , 2015, 3, 936-945.	1.6	65
250	American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. <i>Thyroid</i> , 2015, 25, 760-768.	2.4	204
251	Stereotactic Ablative Radiosurgery for Locally Advanced or Recurrent Skull Base Malignancies with Prior External Beam Radiation Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 65.	1.3	8
252	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. <i>Thyroid</i> , 2015, 25, 1217-1223.	2.4	344

#	ARTICLE	IF	CITATIONS
253	Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker. <i>JAMA Oncology</i> , 2015, 1, 915.	3.4	3
254	A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 480-488.	0.4	123
255	Prevention of Tumor Growth Driven by <i>PIK3CA</i> and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3. <i>Cancer Prevention Research</i> , 2015, 8, 197-207.	0.7	49
256	Surgical trials in head and neck oncology: Renaissance and revolution?. <i>Head and Neck</i> , 2015, 37, 927-930.	0.9	11
257	Early Oral Tongue Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 1104.	1.2	102
258	STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2103-2111.	1.9	19
259	Immune Escape and Immunotherapy of HPV-Related Oropharyngeal Cancer: Has the Future Arrived?. <i>Current Otorhinolaryngology Reports</i> , 2015, 3, 63-72.	0.2	0
260	Cancer of the Oropharynx. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 509-520.	0.6	13
261	Accuracy of early-phase versus dual-phase single-photon emission computed tomography/computed tomography in the localization of Parathyroid disease. <i>Laryngoscope</i> , 2015, 125, 1496-1501.	1.1	15
262	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 2200-2210.	0.4	217
263	Oncologic Outcomes After Transoral Robotic Surgery. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 1043.	1.2	233
264	Immunology and Immunotherapy of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3293-3304.	0.8	566
265	Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 3285-3292.	0.8	134
266	Overview of Advances in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3225-3226.	0.8	39
267	Congenital lobar emphysema presenting as an airway foreign body. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2015, 79, 2450-2452.	0.4	4
268	PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment. <i>Cancer Research</i> , 2015, 75, 508-518.	0.4	184
269	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 2200-2210.	0.4	126
270	Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions. <i>PLoS ONE</i> , 2014, 9, e102452.	1.1	25

#	ARTICLE	IF	CITATIONS
271	Otolaryngology, Head and Neck Surgery. BioMed Research International, 2014, 2014, 1-2.	0.9	42
272	Acute neurorehabilitation: Does a neurosensory and coordinated interdisciplinary programme reduce tracheostomy weaning time and weaning failure?. NeuroRehabilitation, 2014, 34, 809-817.	0.5	14
273	Stereotactic Body Radiotherapy as Primary Treatment for Elderly Patients with Medically Inoperable Head and Neck Cancer. Frontiers in Oncology, 2014, 4, 214.	1.3	35
274	Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head and Neck, 2014, 36, 511-516.	0.9	71
275	Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. Laryngoscope, 2014, 124, 1843-1847.	1.1	44
276	Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 2433-2444.	3.2	118
277	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer, 2014, 120, 624-632.	2.0	51
278	Large-Scale Analysis of B-Cell Epitopes on Influenza Virus Hemagglutinin - Implications for Cross-Reactivity of Neutralizing Antibodies. Frontiers in Immunology, 2014, 5, 38.	2.2	12
279	Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. Oral Oncology, 2014, 50, 662-669.	0.8	9
280	Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: Implications of treatment duration and tumor volume. Head and Neck, 2014, 36, n/a-n/a.	0.9	43
281	Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncology, 2014, 50, 19-26.	0.8	90
282	Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions. Otolaryngology - Head and Neck Surgery, 2014, 151, 272-278.	1.1	50
283	Adjuvant stereotactic body radiotherapy + cetuximab following salvage surgery in previously irradiated head and neck cancer. Laryngoscope, 2014, 124, 1579-1584.	1.1	30
284	Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. Laryngoscope, 2014, 124, 1592-1597.	1.1	49
285	Multi-institutional investigation of the prognostic value of lymph node yield in advanced-stage oral cavity squamous cell carcinoma. Head and Neck, 2014, 36, 1446-1452.	0.9	26
286	Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity. Seminars in Oncology, 2014, 41, 678-684.	0.8	15
287	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer, 2014, 120, 3627-3634.	2.0	445
288	Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion. Journal of Immunology, 2014, 193, 1525-1530.	0.4	149

#	ARTICLE	IF	CITATIONS
289	Clinical Application of Molecular Testing of Fine-needle Aspiration Specimens in Thyroid Nodules. Otolaryngologic Clinics of North America, 2014, 47, 557-571.	0.5	15
290	Identification of the transforming <i>STRN-ALK</i> fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4233-4238.	3.3	230
291	Stereotactic body radiotherapy for recurrent oropharyngeal cancer – Influence of HPV status and smoking history. Oral Oncology, 2014, 50, 1104-1108.	0.8	23
292	Erlotinib, Erlotinib+Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 3289-3298.	3.2	48
293	Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness Analysis. Otolaryngology - Head and Neck Surgery, 2014, 150, 976-982.	1.1	47
294	Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncology, 2014, 50, 780-784.	0.8	27
295	Use of Combined Suspension Laryngoscopy and Jet Ventilation for Y-Shaped Airway Stents Delivery. Annals of Thoracic Surgery, 2014, 97, 2208-2210.	0.7	7
296	Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)., 2014, 2, P69.		0
297	Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 603-610.	0.9	58
298	Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2014, 32, 6033-6033.	0.8	5
299	Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).. Journal of Clinical Oncology, 2014, 32, 6090-6090.	0.8	5
300	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. Journal of Clinical Oncology, 2014, 32, LBA6006-LBA6006.	0.8	6
301	Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).. Journal of Clinical Oncology, 2014, 32, TPS6104-TPS6104.	0.8	6
302	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. Journal of Clinical Oncology, 2014, 32, LBA6006-LBA6006.	0.8	26
303	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. Journal of Clinical Oncology, 2014, 32, 6086-6086.	0.8	0
304	Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2014, 32, TPS3123-TPS3123.	0.8	0
305	Evaluation of computational tools to determine prognostic significance of TP53 mutation in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2014, 32, 6035-6035.	0.8	0
306	Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head and Neck, 2013, 35, 1499-1506.	0.9	20

#	ARTICLE	IF	CITATIONS
307	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 3034-3042.	2.0	180
308	Promising systemic immunotherapies in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 1089-1096.	0.8	101
309	Early squamous cell carcinoma of the oral tongue: Comparing margins obtained from the glossectomy specimen to margins from the tumor bed. <i>Oral Oncology</i> , 2013, 49, 1077-1082.	0.8	64
310	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 602.	1.1	56
311	Extracapsular spread in head and neck carcinoma: Impact of site and human papillomavirus status. <i>Cancer</i> , 2013, 119, 3302-3308.	2.0	159
312	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. <i>Cancer Discovery</i> , 2013, 3, 761-769.	7.7	505
313	A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: A role for transoral robotic surgery. <i>Laryngoscope</i> , 2013, 123, 146-151.	1.1	135
314	Open Access in biomedical sciences: What the current turning point means more specifically to Oral Oncology contributors and readers. <i>Oral Oncology</i> , 2013, 49, 985-986.	0.8	3
315	Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2013, 49, 591-597.	0.8	13
316	Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: A retrospective analysis of the impact of margins and automated PET-CT segmentation. <i>Radiotherapy and Oncology</i> , 2013, 106, 90-95.	0.3	39
317	Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors. <i>Oral Oncology</i> , 2013, 49, 401-406.	0.8	22
318	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013, 45, 791-798.	9.4	394
319	TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1347-1357.	2.0	67
320	<i>RAS</i> Mutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E914-E922.	1.8	128
321	Diagnosis and management of differentiated thyroid cancer using molecular biology. <i>Laryngoscope</i> , 2013, 123, 1059-1064.	1.1	47
322	Accuracy of Computed Tomography in the Prediction of Extracapsular Spread of Lymph Node Metastases in Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 1187.	1.2	83
323	The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC. <i>Clinical Cancer Research</i> , 2013, 19, 889-899.	3.2	57
324	Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1586-1591.	2.1	46

#	ARTICLE	IF	CITATIONS
325	EGFR-mediated tumor immunoescape. <i>Oncolmmunology</i> , 2013, 2, e27215.	2.1	35
326	SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells. <i>Clinical Cancer Research</i> , 2013, 19, 798-808.	3.2	70
327	TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+head and neck cancer cells. <i>Oncolmmunology</i> , 2013, 2, e24677.	2.1	43
328	Oncologic and Functional Outcomes of Partial Laryngeal Surgery for Intermediate-Stage Laryngeal Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 148, 235-242.	1.1	26
329	Correlation of Tumor Marker Expression with Nodal Disease Burden in Metastatic Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 149, 261-268.	1.1	13
330	Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2013, 19, 1858-1872.	3.2	272
331	E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6005-6005.	0.8	19
332	Parathyroidectomy. , 2013, , 2066-2069.		0
333	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. <i>Cancer Discovery</i> , 2012, 2, 694-705.	7.7	260
334	The role of cetuximab in the management of head and neck cancers. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 517-528.	1.4	23
335	Defective NF- κ B Signaling in Metastatic Head and Neck Cancer Cells Leads to Enhanced Apoptosis by Double-Stranded RNA. <i>Cancer Research</i> , 2012, 72, 45-55.	0.4	31
336	Chemokine Receptor 7 (CCR7) Gene Expression Is Regulated by NF- κ B and Activator Protein 1 (AP1) in Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN). <i>Journal of Biological Chemistry</i> , 2012, 287, 3581-3590.	1.6	50
337	In Regard to ACR Appropriateness Criteria of Recurrent Head-and-Neck Cancer After Prior Definitive Radiation. (Int J Radiat Oncol Biol Phys 2011;80:1292-1298). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1322-1323.	0.4	1
338	Re-Irradiation Strategies for Head-and-Neck Cancers: Implications for Stereotactic Body Radiotherapy: In regard to Chen et al (Int J Radiant Oncol Biol Phys 2011;81:1211-1219). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 769-770.	0.4	0
339	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 729-736.	1.7	39
340	Prospective evaluation of patient-reported quality-of-life outcomes following SBRT±cetuximab for locally-recurrent, previously-irradiated head and neck cancer. <i>Radiotherapy and Oncology</i> , 2012, 104, 91-95.	0.3	51
341	Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. <i>Head and Neck</i> , 2012, 34, 1681-1703.	0.9	90
342	Prevention and management of dysphonia during anterior cervical spine surgery. <i>Laryngoscope</i> , 2012, 122, 2179-2183.	1.1	22

#	ARTICLE	IF	CITATIONS
343	A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer. <i>Head & Neck Oncology</i> , 2012, 4, 12.	2.3	21
344	Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: A pilot randomized trial in head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1136-1145.	0.8	11
345	Sentinel lymph node biopsy versus selective neck dissection for detection of metastatic oral squamous cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 693-698.	1.7	11
346	American Thyroid Association Consensus Review and Statement Regarding the Anatomy, Terminology, and Rationale for Lateral Neck Dissection in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 501-508.	2.4	228
347	Rapid molecular detection of metastatic head and neck squamous cell carcinoma as an intraoperative adjunct to sentinel lymph node biopsy. <i>Laryngoscope</i> , 2012, 122, 1020-1030.	1.1	25
348	Molecular biology of adenoid cystic carcinoma. <i>Head and Neck</i> , 2012, 34, 1665-1677.	0.9	63
349	Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. <i>Head and Neck</i> , 2012, 34, 1153-1161.	0.9	37
350	A combined molecular and pathologic score improves risk stratification of thyroid papillary microcarcinoma. <i>Cancer</i> , 2012, 118, 2069-2077.	2.0	139
351	Elective neck dissection: The gold standard for oral cavity carcinoma. <i>Oral Oncology</i> , 2012, 48, 291-292.	0.8	6
352	Targeting ALDH ^{bright} Human Carcinoma-Initiating Cells with ALDH1A1-Specific CD8 ⁺ T Cells. <i>Clinical Cancer Research</i> , 2011, 17, 6174-6184.	3.2	148
353	The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 372-379.	0.6	107
354	The Benefit of Early PET/CT Surveillance in HPV-Associated Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 2011, 137, 1106.	1.5	27
355	Concurrent Cetuximab With Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 165-172.	0.6	106
356	Posttreatment Quality-of-Life Assessment in Patients With Head and Neck Cancer Treated With Intensity-modulated Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 478-482.	0.6	21
357	Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2011, 47, 961-966.	0.8	47
358	The central repeat domain 1 of Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) prevents cis MHC class I peptide presentation. <i>Virology</i> , 2011, 412, 357-365.	1.1	46
359	Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 525-535.	2.0	93
360	Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. <i>Immunologic Research</i> , 2011, 50, 248-254.	1.3	136

#	ARTICLE	IF	CITATIONS
361	EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2011, 9, 168.	1.8	17
362	Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. <i>Journal of Surgical Oncology</i> , 2011, 103, 518-530.	0.8	36
363	Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies. <i>Head and Neck</i> , 2011, 33, 225-231.	0.9	42
364	Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. <i>Head and Neck</i> , 2011, 33, 318-323.	0.9	39
365	Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. <i>Head and Neck</i> , 2011, 33, 504-512.	0.9	134
366	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3390-3397.	1.8	712
367	Intraoperative qRT-PCR for Detection of Lymph Node Metastasis in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1858-1866.	3.2	58
368	Human α -defensin 3 promotes NF- κ B-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck. <i>Carcinogenesis</i> , 2011, 32, 168-174.	1.3	50
369	Immunology of Head and Neck Cancer. , 2011, , 107-119.		1
370	Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience. <i>Laryngoscope</i> , 2010, 120, 71-75.	1.1	35
371	Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 83-91.	1.2	31
372	Response to the letter to the editors by Ottaiano et al.: "Cetuximab-dependent ADCC in cancer: dream or reality?" <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1609-1610.	2.0	0
373	CD8+ T cell recognition of polymorphic wild-type sequence p5365-73 peptides in squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1561-1568.	2.0	13
374	Current concepts and new horizons in conservation laryngeal surgery: An important part of multidisciplinary care. <i>Head and Neck</i> , 2010, 32, 656-665.	0.9	24
375	Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2010, 32, 1412-1421.	0.9	109
376	Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. <i>Laryngoscope</i> , 2010, 120, 734-738.	1.1	58
377	PET-CT staging of the neck in cancers of the oropharynx: patterns of regional and retropharyngeal nodal metastasis. <i>World Journal of Surgical Oncology</i> , 2010, 8, 70.	0.8	23
378	Lipid accumulation and dendritic cell dysfunction in cancer. <i>Nature Medicine</i> , 2010, 16, 880-886.	15.2	539

#	ARTICLE	IF	CITATIONS
379	Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. <i>Journal of Clinical Oncology</i> , 2010, 28, 4390-4399.	0.8	285
380	Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1395-1400.	0.8	324
381	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5294-5300.	0.8	132
382	Community Members as Recruiters of Human Subjects: Ethical Considerations. <i>American Journal of Bioethics</i> , 2010, 10, 3-11.	0.5	65
383	Response to Open Peer Commentaries on "Community Members as Recruiters of Human Subjects: Ethical Considerations". <i>American Journal of Bioethics</i> , 2010, 10, W1-W3.	0.5	3
384	Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. <i>Radiotherapy and Oncology</i> , 2010, 97, 395-398.	0.3	43
385	Fractionated Stereotactic Body Radiation Therapy in the Treatment of Previously-Irradiated Recurrent Head and Neck Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 286-293.	0.6	81
386	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3740-3750.	3.2	196
387	Immunotherapy for head and neck cancer. <i>Oral Oncology</i> , 2009, 45, 747-751.	0.8	7
388	Quantitative expression and immunogenicity of MAGE3 and 6 in upper aerodigestive tract cancer. <i>International Journal of Cancer</i> , 2009, 125, 1912-1920.	2.3	27
389	Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. <i>Current Oncology Reports</i> , 2009, 11, 156-162.	1.8	19
390	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1853-1862.	2.0	148
391	Lack of toxicity of a STAT3 decoy oligonucleotide. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 983-995.	1.1	47
392	Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function. <i>Journal of Immunotherapy</i> , 2009, 32, 465-473.	1.2	37
393	Head and neck cancer immunotherapy: Clinical evaluation. <i>Current Oncology Reports</i> , 2008, 10, 162-169.	1.8	15
394	Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1575-1585.	0.8	39
395	Minimally invasive video-assisted thyroidectomy: Expanded indications and oncologic completeness. <i>Head and Neck</i> , 2008, 30, 1403-1407.	0.9	44
396	Role of Surgery in Limited (T1-2, N0-1) Cancers of the Oropharynx. <i>Laryngoscope</i> , 2008, 118, 2129-2134.	1.1	64

#	ARTICLE	IF	CITATIONS
397	Head and neck cancer. <i>Lancet, The</i> , 2008, 371, 1695-1709.	6.3	1,732
398	Reoperative Parathyroidectomy. <i>Otolaryngologic Clinics of North America</i> , 2008, 41, 1269-1274.	0.5	33
399	Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy. <i>Journal of the National Cancer Institute</i> , 2008, 100, 502-512.	3.0	71
400	STAT3 and immune escape in head and neck squamous cell carcinoma. <i>FASEB Journal</i> , 2008, 22, 1078.23.	0.2	0
401	Autocrine CCR7 signaling is mediated by NF- κ B in SCCHN. <i>FASEB Journal</i> , 2008, 22, 1070.32.	0.2	0
402	CD8+ T cell Recognition of Polymorphic Wild Type Sequence p53 65-73 Peptides in Squamous Cell Carcinoma of the Head and Neck. <i>FASEB Journal</i> , 2008, 22, 1079.15.	0.2	0
403	Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. <i>FASEB Journal</i> , 2008, 22, 1068.22.	0.2	0
404	Head and neck squamous and thyroid carcinomas: multiplexed Luminex approaches for early detection. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 129-136.	1.6	3
405	Early Detection of Head and Neck Cancer: Development of a Novel Screening Tool Using Multiplexed Immunobead-Based Biomarker Profiling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 102-107.	1.1	107
406	NF- κ B Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 5663-5664.	3.2	23
407	Immune Activation by Epidermal Growth Factor Receptor-Specific Monoclonal Antibody Therapy for Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2007, 133, 1277.	1.5	90
408	Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection. <i>Head and Neck</i> , 2007, 29, 163-188.	0.9	209
409	CCR7 Mediates Inflammation-Associated Tumor Progression. <i>Immunologic Research</i> , 2006, 36, 61-72.	1.3	51
410	Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. <i>European Archives of Oto-Rhino-Laryngology</i> , 2006, 263, 313-318.	0.8	25
411	Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3890-3895.	3.2	200
412	Alterations in the T-Cell Receptor Variable β Gene-Restricted Profile of CD8+ T Lymphocytes in the Peripheral Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2006, 12, 2394-2403.	3.2	22
413	Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL. <i>Journal of Immunology</i> , 2006, 176, 3402-3409.	0.4	144
414	Human Leukocyte Antigen (HLA) Class I Defects in Head and Neck Cancer: Molecular Mechanisms and Clinical Significance. <i>Immunologic Research</i> , 2005, 33, 113-134.	1.3	104

#	ARTICLE	IF	CITATIONS
415	Multiplexed Analysis of Serum Cytokines as Biomarkers in Squamous Cell Carcinoma of the Head and Neck Patients. <i>Laryngoscope</i> , 2005, 115, 522-527.	1.1	49
416	Diagnostic Utility of Positron Emission Tomography-Computed Tomography for Predicting Malignancy in Cystic Neck Masses in Adults. <i>Laryngoscope</i> , 2005, 115, 1979-1982.	1.1	18
417	Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 1072-1081.	2.0	101
418	Chemokine C Receptor 7 Expression and Protection of Circulating CD8+ T Lymphocytes from Apoptosis. <i>Clinical Cancer Research</i> , 2005, 11, 7901-7910.	3.2	66
419	Molecular Staging of Cervical Lymph Nodes in Squamous Cell Carcinoma of the Head and Neck. <i>Cancer Research</i> , 2005, 65, 2147-2156.	0.4	105
420	Antitumor Activity of Human Papillomavirus Type 16 E7â€“Specific T Cells against Virally Infected Squamous Cell Carcinoma of the Head and Neck. <i>Cancer Research</i> , 2005, 65, 11146-11155.	0.4	149
421	Exploring websites on cancer clinical trials: An empirical review. <i>Contemporary Clinical Trials</i> , 2005, 26, 530-533.	0.8	11
422	Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. <i>Clinical Immunology</i> , 2005, 116, 27-36.	1.4	30
423	Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): A natural disease model provides insights into viral carcinogenesis. <i>European Journal of Cancer</i> , 2005, 41, 807-815.	1.3	88
424	Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2004, 10, 3755-3762.	3.2	228
425	Progress in Head and Neck Cancer Immunotherapy: Can Tolerance and Immune Suppression Be Reversed?. <i>Orl</i> , 2004, 66, 332-340.	0.6	29
426	Expression Pattern of Chemokine Receptor 6 (CCR6) and CCR7 in Squamous Cell Carcinoma of the Head and Neck Identifies a Novel Metastatic Phenotype. <i>Cancer Research</i> , 2004, 64, 1861-1866.	0.4	149
427	Effect of Human Papillomavirus-16 Infection on CD8+ T-Cell Recognition of a Wild-Type Sequence p53264â€“272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2004, 10, 6929-6937.	3.2	35
428	Elective Neck Dissection and Survival in Patients With Squamous Cell Carcinoma of the Oral Cavity and Oropharynx. <i>Laryngoscope</i> , 2004, 114, 2228-2234.	1.1	91
429	Molecular biology of primary hyperparathyroidism. <i>Otolaryngologic Clinics of North America</i> , 2004, 37, 819-831.	0.5	11
430	Steroid psychosis after head and neck surgery: case report and review of the literature. <i>Otolaryngology - Head and Neck Surgery</i> , 2003, 129, 591-592.	1.1	11
431	Diagnostic assessment of laryngeal cancer. <i>Otolaryngologic Clinics of North America</i> , 2002, 35, 953-969.	0.5	27
432	Functional laryngeal dyskinesia in children and adults. <i>Laryngoscope</i> , 1998, 108, 1520-1523.	1.1	17

#	ARTICLE	IF	CITATIONS
433	An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. Laryngoscope, 1998, 108, 1686-1691.	1.1	36
434	The roboticâ€assisted extended â€œSistrunkâ€ approach for tumors of the upper aerodigestive tract with limited transoral access: First description of oncological and functional outcomes. Head and Neck, 0, , .	0.9	1